FDA approves asthsma indication for Dupixent® (dupilumab
The FDA has approved Dupixent® (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of IL-4 and IL-13. October 19, 2018